Explores detection limits of gDNA assay for assessing minimal residual disease in CML, indicating key implications for treatment decisions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Micheloni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: